{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T21:24:38Z","timestamp":1794259478006,"version":"4.9.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T00:00:00Z","timestamp":1614297600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T00:00:00Z","timestamp":1614297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","award":["SAF2017-87349-R"],"award-info":[{"award-number":["SAF2017-87349-R"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","award":["MDM-2017-0729"],"award-info":[{"award-number":["MDM-2017-0729"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PIE14\/00034"],"award-info":[{"award-number":["PIE14\/00034"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI19\/00144"],"award-info":[{"award-number":["PI19\/00144"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Neurodegener"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>\u03b1-Synuclein has been studied as a potential biomarker for Parkinson\u2019s disease (PD) with no concluding results. Accordingly, there is an urgent need to find out reliable specific biomarkers for PD. GPR37 is an orphan G protein-coupled receptor that toxically accumulates in autosomal recessive juvenile parkinsonism. Here, we investigated whether GPR37 is upregulated in sporadic PD, and thus a suitable potential biomarker for PD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>GPR37 protein density and mRNA expression in postmortem substantia nigra (SN) from PD patients were analysed by immunoblot and RT-qPCR, respectively. The presence of peptides from the N-terminus-cleaved domain of GPR37 (i.e. ecto-GPR37) in human cerebrospinal fluid (CSF) was determined by liquid chromatography-mass spectrometric analysis. An engineered in-house nanoluciferase-based immunoassay was used to quantify ecto-GPR37 in CSF samples from neurological control (NC) subjects, PD patients and Alzheimer\u2019s disease (AD) patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>GPR37 protein density and mRNA expression were significantly augmented in sporadic PD. Increased amounts of ecto-GPR37 peptides in the\u00a0CSF samples from PD patients were identified by mass spectrometry and quantified by the in-house ELISA method. However, the CSF total \u03b1-synuclein level in PD patients did not differ from that in NC subjects. Similarly, the cortical GPR37 mRNA expression and CSF ecto-GPR37 levels in AD patients were also unaltered.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>GPR37 expression is increased in SN of sporadic PD patients. The ecto-GPR37 peptides are significantly increased in the\u00a0CSF of PD patients, but not in AD patients. These results open perspectives and encourage further clinical studies to confirm the validity and utility of ecto-GPR37 as a potential PD biomarker.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s40035-021-00232-7","type":"journal-article","created":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T05:18:21Z","timestamp":1614316701000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Ecto-GPR37: a potential biomarker for Parkinson\u2019s disease"],"prefix":"10.1186","volume":"10","author":[{"given":"Xavier","family":"Morat\u00f3","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Garcia-Esparcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Argerich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franc","family":"Llorens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inga","family":"Zerr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Paslawski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Borr\u00e0s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduard","family":"Sabid\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulla E.","family":"Pet\u00e4j\u00e4-Repo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00edctor","family":"Fern\u00e1ndez-Due\u00f1as","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isidro","family":"Ferrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Svenningsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0832-3739","authenticated-orcid":false,"given":"Francisco","family":"Ciruela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,26]]},"reference":[{"issue":"6","key":"232_CR1","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S1474-4422(06)70471-9","volume":"5","author":"LM de Lau","year":"2006","unstructured":"de Lau LM, Breteler MM. Epidemiology of Parkinson\u2019s disease. Lancet Neurol. 2006;5(6):525\u201335.","journal-title":"Lancet Neurol"},{"key":"232_CR2","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1146\/annurev.biochem.74.082803.133400","volume":"74","author":"MR Cookson","year":"2005","unstructured":"Cookson MR. The biochemistry of Parkinson\u2019s disease. Annu Rev Biochem. 2005;74:29\u201352.","journal-title":"Annu Rev Biochem"},{"issue":"3","key":"232_CR3","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/nrneurol.2010.4","volume":"6","author":"K Blennow","year":"2010","unstructured":"Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010;6(3):131\u201344.","journal-title":"Nat Rev Neurol"},{"issue":"3","key":"232_CR4","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/nrneurol.2013.10","volume":"9","author":"L Parnetti","year":"2013","unstructured":"Parnetti L, Castrioto A, Chiasserini D, Persichetti E, Tambasco N, El-Agnaf O, et al. Cerebrospinal fluid biomarkers in Parkinson disease. Nat Rev Neurol. 2013;9(3):131\u201340.","journal-title":"Nat Rev Neurol"},{"key":"232_CR5","doi-asserted-by":"crossref","unstructured":"Parnetti L, Gaetani L, Eusebi P, Paciotti S, Hansson O. El-Agnaf O, et al. CSF and blood biomarkers for Parkinson\u2019s disease.\u00a0Lancet Neurol.\u00a02019;18(6):573\u201386.","DOI":"10.1016\/S1474-4422(19)30024-9"},{"issue":"1","key":"232_CR6","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/S0169-328X(97)00336-7","volume":"54","author":"PJ Donohue","year":"1998","unstructured":"Donohue PJ, Shapira H, Mantey SA, Hampton LL, Jensen RT, Battey JF. A human gene encodes a putative G protein-coupled receptor highly expressed in the central nervous system. Brain Res Mol Brain Res. 1998;54(1):152\u201360.","journal-title":"Brain Res Mol Brain Res"},{"issue":"1","key":"232_CR7","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/jnc.13109","volume":"134","author":"JP Lopes","year":"2015","unstructured":"Lopes JP, Morat\u00f3 X, Souza C, Pinhal C, Machado NJ, Canas PM, et al. The role of Parkinson\u2019s disease-associated receptor GPR37 in the hippocampus: functional interplay with the adenosinergic system. J Neurochem. 2015;134(1):135\u201346.","journal-title":"J Neurochem"},{"key":"232_CR8","doi-asserted-by":"crossref","unstructured":"Yang HJ, Vainshtein A, Maik-Rachline G, Peles E. G protein-coupled receptor 37 is a negative regulator of oligodendrocyte differentiation and myelination. Nat Commun. 2016;7:10884.","DOI":"10.1038\/ncomms10884"},{"issue":"7","key":"232_CR9","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/S0092-8674(01)00407-X","volume":"105","author":"Y Imai","year":"2001","unstructured":"Imai Y, Soda M, Inoue H, Hattori N, Mizuno Y, Takahashi R. An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin. Cell. 2001;105(7):891\u2013902.","journal-title":"Cell."},{"issue":"6676","key":"232_CR10","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/33416","volume":"392","author":"T Kitada","year":"1998","unstructured":"Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 1998;392(6676):605\u20138.","journal-title":"Nature."},{"issue":"3","key":"232_CR11","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/77060","volume":"25","author":"H Shimura","year":"2000","unstructured":"Shimura H, Hattori N, Kubo S, Mizuno Y, Asakawa S, Minoshima S, et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet. 2000;25(3):302\u20135.","journal-title":"Nat Genet"},{"issue":"27","key":"232_CR12","doi-asserted-by":"publisher","first-page":"10189","DOI":"10.1073\/pnas.0403661101","volume":"101","author":"D Marazziti","year":"2004","unstructured":"Marazziti D, Golini E, Mandillo S, Magrelli A, Witke W, Matteoni R, et al. Altered dopamine signaling and MPTP resistance in mice lacking the Parkinson\u2019s disease-associated GPR37\/parkin-associated endothelin-like receptor. Proc Natl Acad Sci U S A. 2004;101(27):10189\u201394.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"232_CR13","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1242\/jcs.176115","volume":"129","author":"SO Mattila","year":"2016","unstructured":"Mattila SO, Tuusa JT, Pet\u00e4j\u00e4-Repo UE. The Parkinson\u2019s-disease-associated receptor GPR37 undergoes metalloproteinase-mediated N-terminal cleavage and ectodomain shedding. J Cell Sci. 2016;129(7):1366\u201377.","journal-title":"J Cell Sci"},{"issue":"1","key":"232_CR14","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1006\/exnr.2002.8019","volume":"178","author":"S Lorenzl","year":"2002","unstructured":"Lorenzl S, Albers DS, Narr S, Chirichigno J, Beal MF. Expression of MMP-2, MMP-9, and MMP-1 and their endogenous counterregulators TIMP-1 and TIMP-2 in postmortem brain tissue of Parkinson\u2019s disease. Exp Neurol. 2002;178(1):13\u201320.","journal-title":"Exp Neurol"},{"issue":"3","key":"232_CR15","doi-asserted-by":"publisher","first-page":"711","DOI":"10.3233\/JAD-143186","volume":"48","author":"FH Duits","year":"2015","unstructured":"Duits FH, Hernandez-Guillamon M, Montaner J, Goos JDC, Monta\u00f1ola A, Wattjes MP, et al. Matrix Metalloproteinases in Alzheimer\u2019s disease and concurrent cerebral microbleeds. J Alzheimers Dis. 2015;48(3):711\u201320.","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"232_CR16","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/S0304-3940(00)01418-X","volume":"291","author":"A Leake","year":"2000","unstructured":"Leake A, Morris CM, Whateley J. Brain matrix metalloproteinase 1 levels are elevated in Alzheimer\u2019s disease. Neurosci Lett. 2000;291(3):201\u20133.","journal-title":"Neurosci Lett"},{"issue":"3","key":"232_CR17","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1111\/jnc.12196","volume":"125","author":"J Gand\u00eda","year":"2013","unstructured":"Gand\u00eda J, Fern\u00e1ndez-Due\u00f1as V, Morat\u00f3 X, Caltabiano G, Gonz\u00e1lez-Mu\u00f1iz R, Pardo L, et al. The Parkinson\u2019s disease-associated GPR37 receptor-mediated cytotoxicity is controlled by its intracellular cysteine-rich domain. J Neurochem. 2013;125(3):362\u201372.","journal-title":"J Neurochem"},{"issue":"1","key":"232_CR18","doi-asserted-by":"publisher","first-page":"9452","DOI":"10.1038\/s41598-017-10147-x","volume":"7","author":"X Morat\u00f3","year":"2017","unstructured":"Morat\u00f3 X, Luj\u00e1n R, L\u00f3pez-Cano M, Gand\u00eda J, Stagljar I, Watanabe M, et al. The Parkinson\u2019s disease-associated GPR37 receptor interacts with striatal adenosine A2A receptor controlling its cell surface expression and function in vivo. Sci Rep. 2017;7(1):9452.","journal-title":"Sci Rep"},{"issue":"7","key":"232_CR19","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1111\/j.1742-4658.2012.08518.x","volume":"279","author":"R Ravid","year":"2012","unstructured":"Ravid R, Ferrer I. Brain banks as key part of biochemical and molecular studies on cerebral cortex involvement in Parkinson\u2019s disease. FEBS J. 2012;279(7):1167\u201376.","journal-title":"FEBS J"},{"issue":"3","key":"232_CR20","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s10561-008-9077-0","volume":"9","author":"I Ferrer","year":"2008","unstructured":"Ferrer I, Martinez A, Boluda S, Parchi P, Barrachina M. Brain banks: benefits, limitations and cautions concerning the use of post-mortem brain tissue for molecular studies. Cell Tissue Bank. 2008;9(3):181\u201394.","journal-title":"Cell Tissue Bank"},{"issue":"2","key":"232_CR21","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","volume":"24","author":"H Braak","year":"2003","unstructured":"Braak H, Del Tredici K, R\u00fcb U, de Vos RAI, Jansen Steur ENH, Braak E. Staging of brain pathology related to sporadic Parkinson\u2019s disease. Neurobiol Aging. 2003;24(2):197\u2013211.","journal-title":"Neurobiol Aging"},{"issue":"4","key":"232_CR22","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/BF00308809","volume":"82","author":"H Braak","year":"1991","unstructured":"Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239\u201359.","journal-title":"Acta Neuropathol"},{"key":"232_CR23","volume-title":"Members of the UPDRS development committee. Unified Parkinson disease rating scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, editors. Recent developments in Parkinson\u2019s disease Vol II","author":"S Fahn","year":"1987","unstructured":"Fahn S, Elton R. Members of the UPDRS development committee. Unified Parkinson disease rating scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, editors. Recent developments in Parkinson\u2019s disease Vol II. Florham Park, NJ: Macmillan Health Care Information; 1987."},{"issue":"9","key":"232_CR24","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/mds.20213","volume":"19","author":"CG Goetz","year":"2004","unstructured":"Goetz CG, Poewe W, Rascol O, Sampaio C, Stebbins GT, Counsell C, et al. Movement Disorder Society task force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord. 2004;19(9):1020\u20138.","journal-title":"Mov Disord"},{"key":"232_CR25","doi-asserted-by":"crossref","unstructured":"Nasreddine ZS, Phillips NA,\u00a0B\u00e9dirian\u00a0V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695\u20139.","DOI":"10.1111\/j.1532-5415.2005.53221.x"},{"issue":"7","key":"232_CR26","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1002\/mds.20844","volume":"21","author":"KR Chaudhuri","year":"2006","unstructured":"Chaudhuri KR, Martinez-Martin P, Schapira AHV, Stocchi F, Sethi K, Odin P, et al. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson\u2019s disease: the NMSQuest study. Mov Disord. 2006;21(7):916\u201323.","journal-title":"Mov Disord"},{"issue":"6","key":"232_CR27","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","volume":"67","author":"AS Zigmond","year":"1983","unstructured":"Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361\u201370.","journal-title":"Acta Psychiatr Scand"},{"issue":"15","key":"232_CR28","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1002\/mds.23429","volume":"25","author":"CL Tomlinson","year":"2010","unstructured":"Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson\u2019s disease. Mov Disord. 2010;25(15):2649\u201353.","journal-title":"Mov Disord"},{"key":"232_CR29","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.neulet.2013.09.003","volume":"555","author":"I Bj\u00f6rkhem","year":"2013","unstructured":"Bj\u00f6rkhem I, L\u00f6vgren-Sandblom A, Leoni V, Meaney S, Brodin L, Salveson L, et al. Oxysterols and Parkinson\u2019s disease: evidence that levels of 24S-hydroxycholesterol in cerebrospinal fluid correlates with the duration of the disease. Neurosci Lett. 2013;555:102\u20135.","journal-title":"Neurosci Lett"},{"issue":"3","key":"232_CR30","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(3):263\u20139.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"232_CR31","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/ilar.38.1.41","volume":"38","author":"JD Clark","year":"1997","unstructured":"Clark JD, Gebhart GF, Gonder JC, Keeling ME, Kohn DF. Special report: the 1996 guide for the care and use of laboratory animals. ILAR J. 1997;38(1):41\u20138.","journal-title":"ILAR J"},{"key":"232_CR32","doi-asserted-by":"crossref","unstructured":"Durrenberger PF, Fernando S, Kashefi SN, Ferrer I, Hauw JJ, Seilhean D, et al. Effects of antemortem and postmortem variables on human brain mRNA quality: a BrainNet Europe study. J Neuropathol Exp Neurol. 2010;69(1):70\u201381.","DOI":"10.1097\/NEN.0b013e3181c7e32f"},{"issue":"3","key":"232_CR33","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.neuint.2006.01.018","volume":"49","author":"M Barrachina","year":"2006","unstructured":"Barrachina M, Casta\u00f1o E, Ferrer I. TaqMan PCR assay in the control of RNA normalization in human post-mortem brain tissue. Neurochem Int. 2006;49(3):276\u201384.","journal-title":"Neurochem Int"},{"key":"232_CR34","doi-asserted-by":"crossref","unstructured":"Longo PA, Kavran JM, Kim MS, Leahy DJ. Transient mammalian cell transfection with polyethylenimine (PEI). Methods Enzymol. 2013;529:227\u201340.","DOI":"10.1016\/B978-0-12-418687-3.00018-5"},{"issue":"3","key":"232_CR35","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1002\/ana.20064","volume":"55","author":"T Murakami","year":"2004","unstructured":"Murakami T, Shoji M, Imai Y, Inoue H, Kawarabayashi T, Matsubara E, et al. Pael-R is accumulated in Lewy bodies of Parkinson\u2019s disease. Ann Neurol. 2004;55(3):439\u201342.","journal-title":"Ann Neurol"},{"issue":"D1","key":"232_CR36","doi-asserted-by":"publisher","first-page":"D440","DOI":"10.1093\/nar\/gkx1109","volume":"46","author":"G P\u00e1ndy-Szekeres","year":"2018","unstructured":"P\u00e1ndy-Szekeres G, Munk C, Tsonkov TM, Mordalski S, Harps\u00f8e K, Hauser AS, et al. GPCRdb in 2018: adding GPCR structure models and ligands. Nucleic Acids Res. 2018;46(D1):D440\u20136.","journal-title":"Nucleic Acids Res"},{"issue":"23","key":"232_CR37","doi-asserted-by":"publisher","first-page":"9529","DOI":"10.1073\/pnas.1219004110","volume":"110","author":"RC Meyer","year":"2013","unstructured":"Meyer RC, Giddens MM, Schaefer SA, Hall RA. GPR37 and GPR37L1 are receptors for the neuroprotective and glioprotective factors prosaptide and prosaposin. Proc Natl Acad Sci U S A. 2013;110(23):9529\u201334.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"232_CR38","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1002\/glia.23480","volume":"66","author":"B Liu","year":"2018","unstructured":"Liu B, Mosienko V, Vaccari Cardoso B, Prokudina D, Huentelman M, Teschemacher AG, et al. Glio- and neuro-protection by prosaposin is mediated by orphan G-protein coupled receptors GPR37L1 and GPR37. Glia. 2018;66(11):2414\u201326.","journal-title":"Glia."},{"key":"232_CR39","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.neuropharm.2018.11.009","volume":"152","author":"E Hertz","year":"2019","unstructured":"Hertz E, Terenius L, Vukojevi\u0107 V, Svenningsson P. GPR37 and GPR37L1 differently interact with dopamine 2 receptors in live cells. Neuropharmacology. 2019;152:51\u20137.","journal-title":"Neuropharmacology."},{"issue":"5","key":"232_CR40","doi-asserted-by":"publisher","first-page":"712","DOI":"10.15252\/embr.201643585","volume":"18","author":"BS Berger","year":"2017","unstructured":"Berger BS, Acebron SP, Herbst J, Koch S, Niehrs C. Parkinson\u2019s disease-associated receptor GPR37 is an ER chaperone for LRP6. EMBO Rep. 2017;18(5):712\u201325.","journal-title":"EMBO Rep"},{"issue":"8","key":"232_CR41","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.tips.2017.05.001","volume":"38","author":"R Flaumenhaft","year":"2017","unstructured":"Flaumenhaft R, De Ceunynck K. Targeting PAR1: now what? Trends Pharmacol Sci. 2017;38(8):701\u201316.","journal-title":"Trends Pharmacol Sci"},{"issue":"13","key":"232_CR42","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1002\/mds.26036","volume":"29","author":"W Sako","year":"2014","unstructured":"Sako W, Murakami N, Izumi Y, Kaji R. Reduced alpha-synuclein in cerebrospinal fluid in synucleinopathies: evidence from a meta-analysis. Mov Disord. 2014;29(13):1599\u2013605.","journal-title":"Mov Disord"},{"issue":"8","key":"232_CR43","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1002\/mds.23670","volume":"26","author":"L Parnetti","year":"2011","unstructured":"Parnetti L, Chiasserini D, Bellomo G, Giannandrea D, de Carlo C, Qureshi MM, et al. Cerebrospinal fluid tau\/\u03b1-synuclein ratio in Parkinson\u2019s disease and degenerative dementias. Mov Disord. 2011;26(8):1428\u201335.","journal-title":"Mov Disord"},{"issue":"10","key":"232_CR44","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1002\/mds.27110","volume":"32","author":"P Eusebi","year":"2017","unstructured":"Eusebi P, Giannandrea D, Biscetti L, Abraha I, Chiasserini D, Orso M, et al. Diagnostic utility of cerebrospinal fluid \u03b1-synuclein in Parkinson\u2019s disease: a systematic review and meta-analysis. Mov Disord. 2017;32(10):1389\u2013400.","journal-title":"Mov Disord"},{"issue":"9","key":"232_CR45","doi-asserted-by":"publisher","first-page":"645","DOI":"10.3109\/00207454.2014.961454","volume":"125","author":"L Wang","year":"2015","unstructured":"Wang L, Gao L, Tang H, Nie K, Wang L, Zhao J, et al. Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson\u2019s disease diagnosis: a systematic review and meta-analysis. Int J Neurosci. 2015;125(9):645\u201354.","journal-title":"Int J Neurosci"},{"issue":"10","key":"232_CR46","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1002\/acn3.338","volume":"3","author":"G Fairfoul","year":"2016","unstructured":"Fairfoul G, McGuire LI, Pal S, Ironside JW, Neumann J, Christie S, et al. Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies. Ann Clin Transl Neurol. 2016;3(10):812\u20138.","journal-title":"Ann Clin Transl Neurol"},{"issue":"7","key":"232_CR47","doi-asserted-by":"publisher","first-page":"4395","DOI":"10.1118\/1.4730289","volume":"39","author":"F Segovia","year":"2012","unstructured":"Segovia F, G\u00f3rriz JM, Ram\u00edrez J, \u00c1lvarez I, Jim\u00e9nez-Hoyuela JM, Ortega SJ. Improved parkinsonism diagnosis using a partial least squares based approach. Med Phys. 2012;39(7):4395\u2013403.","journal-title":"Med Phys"},{"issue":"15","key":"232_CR48","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1212\/WNL.0000000000003810","volume":"88","author":"L Saari","year":"2017","unstructured":"Saari L, Kivinen K, Gardberg M, Joutsa J, Noponen T, Kaasinen V. Dopamine transporter imaging does not predict the number of nigral neurons in Parkinson disease. Neurology. 2017;88(15):1461\u20137.","journal-title":"Neurology."},{"issue":"1","key":"232_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2011.10.007","volume":"8","author":"BT Hyman","year":"2012","unstructured":"Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, et al. National Institute on Aging-Alzheimer\u2019s association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease. Alzheimers Dement. 2012;8(1):1\u201313.","journal-title":"Alzheimers Dement"}],"container-title":["Translational Neurodegeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40035-021-00232-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40035-021-00232-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40035-021-00232-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T21:57:24Z","timestamp":1724536644000},"score":1,"resource":{"primary":{"URL":"https:\/\/translationalneurodegeneration.biomedcentral.com\/articles\/10.1186\/s40035-021-00232-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,26]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["232"],"URL":"https:\/\/doi.org\/10.1186\/s40035-021-00232-7","relation":{},"ISSN":["2047-9158"],"issn-type":[{"value":"2047-9158","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,26]]},"assertion":[{"value":"24 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the regional ethics committee for medical research in Stockholm (2011\/500\u201331\/1 and 2012\/2224\u201332\/4). Animals were housed and tested in compliance with the guidelines described in the Materials and Methods section and all animal protocols were approved by the University of Barcelona Committee on Animal Use and Care (DAAM_7035). The use of human brain biopsies was approved by the Bellvitge Hospital Ethic Committee for Research (BB19_024).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interest relevant to the work conducted in the present study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8"}}